Literature DB >> 11987673

[Cardiovascular risk in patients with chronic renal failure. Patients in renal replacement therapy].

A Cases1, M Vera, J M López Gómez.   

Abstract

Dialysis patients constitute a high-risk subset of patients for developing cardiovascular disease, which accounts for nearly 50% of deaths. After stratification for age, race and gender, cardiovascular mortality is 10-20 times higher in dialysis patients than in the general population. Cardiovascular disease in this population cannot be fully explained by the high prevalence of classical cardiovascular risk factors (age, hypertension, diabetes, hyperlipidemia, smoking, etc.). Thus, the involvement of "new" cardiovascular risk factors (hyperhomocysteinemia, hyperfibrinogenemia, high lipoprotein (a) levels, oxidative stress, inflammation, etc.), and uremia-related factors (anemia, impaired calcium-phosphorus metabolism, hyperparathyroidism, accumulation of endogenous inhibitors of nitric oxide synthesis, etc.) has been also invoked to play a role in the increased cardiovascular risk in these patients. Endothelial dysfunction is the initial event in the development of atherosclerosis. Uremic patients exhibit an endothelial dysfunction, even before starting dialysis, which persists o is even aggravated under dialysis treatment. Uremic patients must be considered at high risk of developing cardiovascular disease. Thus cardiovascular risk factors in these patients should be managed early, aggressive and multifactorially in order to reduce their high cardiovascular morbidity and mortality.

Entities:  

Mesh:

Year:  2002        PMID: 11987673

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  5 in total

1.  Doppler assessment of brachial artery flow as a measure of endothelial dysfunction in pediatric chronic renal failure.

Authors:  Gehan Hussein; Yasser Bughdady; Manal E Kandil; Hafez M Bazaraa; Heba Taher
Journal:  Pediatr Nephrol       Date:  2008-06-10       Impact factor: 3.714

2.  Erythropoietin therapy improves endothelial function in patients with non-dialysis chronic kidney disease and anemia (EARNEST-CKD): A clinical study.

Authors:  Jina Lim; Chung Jo Yu; Hoon Yu; Sang Jin Ha
Journal:  Medicine (Baltimore)       Date:  2021-10-22       Impact factor: 1.817

3.  Efficacy of Oral Administration of Allium sativum Powder "Garlic Extract" on Lipid Profile, Inflammation, and Cardiovascular Indices among Hemodialysis Patients.

Authors:  Masoumeh Asgharpour; Armin Khavandegar; Parastoo Balaei; Noora Enayati; Parham Mardi; Amirhesam Alirezaei; Mahmood Bakhtiyari
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-17       Impact factor: 2.629

4.  Darbepoetin alpha reduces oxidative stress and chronic inflammation in atherosclerotic lesions of apo E deficient mice in experimental renal failure.

Authors:  Nicole Arend; Karl F Hilgers; Valentina Campean; Britta Karpe; Nada Cordasic; Bernd Klanke; Kerstin Amann
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

5.  Hemodialysis is a strong risk factor for post-endoscopic sphincterotomy bleeding in patients with choledocholithiasis.

Authors:  So Nakaji; Nobuto Hirata; Hiroki Matsui; Toshiyasu Shiratori; Masayoshi Kobayashi; Shigenobu Yoshimura; Keisuke Kanda; Natsuki Kawamitsu; Hisato Harasawa
Journal:  Endosc Int Open       Date:  2018-05-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.